| Attribute |
Value |
| 52 Week Change |
-0.9451852 |
| Address1 |
2,929 North Commerce Parkway |
| All Time High |
1,866.0 |
| All Time Low |
1.47 |
| Ask |
1.99 |
| Ask Size |
2 |
| Average Analyst Rating |
2.0 - Buy |
| Average Daily Volume10 Day |
53,890 |
| Average Daily Volume3 Month |
377,095 |
| Average Volume |
377,095 |
| Average Volume10Days |
53,890 |
| Beta |
2.419 |
| Bid |
1.19 |
| Bid Size |
2 |
| Book Value |
4.592 |
| City |
Miramar |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Country |
United States |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
1.3706 |
| Current Ratio |
0.061 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,790,726,400 |
| Day High |
1.45 |
| Day Low |
1.3 |
| Debt To Equity |
88.337 |
| Display Name |
HCW Biologics |
| Dividend Yield |
0.0 |
| Ebitda |
-5,584,538 |
| Ebitda Margins |
-0.83088994 |
| Enterprise To Ebitda |
-1.529 |
| Enterprise To Revenue |
1.27 |
| Enterprise Value |
8,537,797 |
| Eps Forward |
-0.55 |
| Eps Trailing Twelve Months |
-19.84 |
| Esg Populated |
0 |
| Exchange |
NCM |
| Exchange Data Delayed By |
15 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fax |
954 842 2037 |
| Fifty Day Average |
2.4219 |
| Fifty Day Average Change |
-1.0513 |
| Fifty Day Average Change Percent |
-0.4340807 |
| Fifty Two Week Change Percent |
-94.51852 |
| Fifty Two Week High |
27.3 |
| Fifty Two Week High Change |
-25.9294 |
| Fifty Two Week High Change Percent |
-0.9497949 |
| Fifty Two Week Low |
1.3 |
| Fifty Two Week Low Change |
0.07060003 |
| Fifty Two Week Low Change Percent |
0.054307718 |
| Fifty Two Week Range |
1.3 - 27.3 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
1,626,787,800,000 |
| Float Shares |
1,683,156 |
| Forward Eps |
-0.55 |
| Forward P E |
-2.4919999 |
| Free Cashflow |
-11,661,168 |
| Full Exchange Name |
NasdaqCM |
| Full Time Employees |
35 |
| Fullday Change |
-0.109400034 |
| Fullday Change Percent |
-7.391894 |
| Fullday Price |
1.3706 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
0.95914 |
| Gross Profits |
6,446,566 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.07983 |
| Held Percent Institutions |
0.07412 |
| Implied Shares Outstanding |
2,236,324 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Ipo Expected Date |
2,021-07-20 |
| Language |
en-US |
| Last Fiscal Year End |
1,767,139,200 |
| Last Split Date |
1,782,777,600 |
| Last Split Factor |
1:6 |
| Long Business Summary |
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases. The company also develops HCW9201, a fusion protein designed as a reagent to use in the production of natural killer (NK) cell-based therapies; HCW9206, a fusion protein designed as a reagent to use in the production of CAR-therapies for the treatment of infectious diseases; and HCW11-006, a multi-functional immune cell stimulator. It has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecule. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida. |
| Long Name |
HCW Biologics Inc. |
| Market |
us_market |
| Market Cap |
3,065,105 |
| Market State |
REGULAR |
| Max Age |
86,400 |
| Message Board Id |
finmb_628452149 |
| Most Recent Quarter |
1,782,777,600 |
| Net Income To Common |
-21,410,162 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
3,048,297 |
| Number Of Analyst Opinions |
1 |
| Open |
1.3 |
| Operating Cashflow |
-12,136,822 |
| Operating Margins |
-23.35573 |
| Phone |
954 842 2024 |
| Previous Close |
1.48 |
| Price Hint |
4 |
| Price To Book |
0.2984756 |
| Price To Sales Trailing12 Months |
0.45603633 |
| Profit Margins |
-0.83049005 |
| Quick Ratio |
0.041 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
buy |
| Recommendation Mean |
2.0 |
| Region |
US |
| Regular Market Change |
-0.109400034 |
| Regular Market Change Percent |
-7.391894 |
| Regular Market Day High |
1.45 |
| Regular Market Day Low |
1.3 |
| Regular Market Day Range |
1.3 - 1.45 |
| Regular Market Open |
1.3 |
| Regular Market Previous Close |
1.48 |
| Regular Market Price |
1.3706 |
| Regular Market Time |
1,791,907,663 |
| Regular Market Volume |
1,991,275 |
| Return On Assets |
-0.13885 |
| Return On Equity |
-1.51359 |
| Revenue Growth |
19.697 |
| Revenue Per Share |
8.534 |
| Sand P52 Week Change |
0.17502642 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
2,236,324 |
| Shares Percent Shares Out |
0.0273 |
| Shares Short |
60,941 |
| Shares Short Previous Month Date |
1,788,134,400 |
| Shares Short Prior Month |
34,136 |
| Short Name |
HCW Biologics Inc. |
| Short Percent Of Float |
0.028499998 |
| Short Ratio |
0.07 |
| Source Interval |
15 |
| State |
FL |
| Symbol |
HCWB |
| Target High Price |
8.0 |
| Target Low Price |
8.0 |
| Target Mean Price |
8.0 |
| Target Median Price |
8.0 |
| Total Cash |
741,324 |
| Total Cash Per Share |
0.404 |
| Total Debt |
6,561,361 |
| Total Revenue |
6,721,186 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-19.84 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
4.54204 |
| Two Hundred Day Average Change |
-3.17144 |
| Two Hundred Day Average Change Percent |
-0.6982413 |
| Type Disp |
Equity |
| Volume |
1,991,275 |
| Website |
https://www.hcwbiologics.com |
| Zip |
33,025 |